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Introduction:Many drugs such as antidepressants, anticonvulsants and 
opioidshave been used in the management of Chemotherapy Induced Peripheral 
Neuropathy. However, the reporting quality of their Randomized Controlled Trials 
(RCTs) has not been yet assessed. 
Objective: This study aims to assess the reporting quality of RCTS for pharmaco-
therapeutic drugs usually used in the treatment of Chemotherapy Induced 
NeuropathicPain published from 2005-2015, using the CONSORT (Consolidated 
Standards of Reporting Trials) 2010 statement. 
Methods: PubMed and Cochrane CENTRAL databases were searched in August 
2016 for relative RCT reports. Each item of the CONSORT 2010 checklist was 
scored with 1 if clearly reported or 0 otherwise. Total CONSORT scores and 
frequencies of reporting each item were calculated. Comparisons between pre- 
and post- CONSORT 2010 periods were made with Mann- Whitney and Fisher 
exact tests. 
Results: The total CONSORT score of the 9 articles, in the combined 2005-2015 
period, ranged from 20 to 28. Items of the CONSORT checklist were reported in 
different sequences. 6 items were recorded in 100% of the articles though 11 
items were reported in less than 50%. Between pre- and post-CONSORT 2010 
period groups, we can see important progress in reporting Additional 
analysis(Item12b, p=0,003<0.05) and Generalisability (Item2, p=0,023<0.05). 
Conclusion: Some aspects of the study are inadequately reported. To raise the 
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relatedadverseeffect of anticancer drugs including platinums, 
taxanes, epothilones, vinca alkaloids, and newer agents such as 
bortezomiboccurring in ~20% of patients given standard doses 
of chemotherapy, 
althoughthispercentagevariesdependingonchemotherapyregim
ens,durationofexposure,andassessmentmethods and in almost 
100% of patients treated with high doses.It affectslong-
termqualityoflife 
andhasthepotentialtoresultinchemotherapydosereductionsand
/orearlydiscontinuation. CIPN presents clinically as deficits in 
sensory, motor, and sometimes autonomic function. Sensory 
disturbances range from a mild tingling sensation to 
spontaneous burning pain and hypersensitivity to stimuli. These 
symptoms often affect both hands and feet and may spread 
into a 'glove/stocking' distribution. Symptoms are usually 
symmetrical distally but may be more severe unilaterally. 
Although dependent on the specific agent, the feet are often 
affected first. Symptoms may occur at any time during the 
course of chemotherapy (seen with paclitaxel), or even after 
termination (commonly known as "coasting"), which refers to 
neuropathic symptoms that present after discontinuation of 
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anticancer treatment, and which may continue or worsen over 
weeks or months. This phenomenon suggests that there is 
ongoing neuronal damage even after discontinuation of 
anticancer drugs.  
As far as the pathophysiology of CIPN is concerned, many 
mechanisms including mitochondrial dysfunction, various pain 
mediators and abnormal spontaneous discharge in A and C 
fibershave been suggested. It is a fact that CIPN is usually 
under-treated, partly because of the lack of a consensus on its 
pathophysiology.  
And although some data suggest that certain substances may 
prevent CIPN, no treatments have been demonstrated to 
prevent and treat it effectively. Pregabalin may be used to 
decrease neuropathy after oxaliplatin treatment. Duloxetine 
showed modest analgesic efficacy in CIPN (paclitaxel- and 
oxaliplatin-induced) patients compared with a placebo in a 
randomized clinical trial. These data support a moderate 
recommendation for CIPN treatment. Among antidepressants, 
venlafaxine has been shown to reduce the incidence of CIPN, 
albeit with some side effects. Cannabinoids may be a new 
treatment option for CIPN, and should be evaluated in robust 
RCTs. Although tricyclic antidepressants (such as nortriptyline 
or desipramine), gabapentin, and a topical gel containing 
baclofen (10 mg), amitriptyline HCL (40 mg), and ketamine (20 
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mg) yielded inconclusive data in CIPN trials, these agents may 
constitute the remaining CIPN treatment options. 
RCTS are considered as a gold standard in the evaluating 
process of new interventions through the comparison with 
standard treatment or placebo. In order to provide strong 
medical evidence, they must lie on strict methodology and 
should be clearly and adequately reported. Randomization, 
allocation, blinding are some key aspects of the value of a trial. 
Implementation weaknesses and/or poor reporting can mislead 
to biased results affecting health care providers and even 
health policy makers. Additionally, a complete and transparent 
RCT report can elucidate any methodological drawbacks of the 
study, revealing its credibility. 
Aiming to improve the reporting quality of RCTs, the CONSORT 
(Consolidated Standards of Reporting Trials) statement was first 
developed in 1996. Since then it has been revised twice, in 2001 
and in 2010. The last revision has provided a 25-item checklist 
that every trial should address in its report (see Appendix), and 
a flow diagram describing the subjects flow through the trial 
procedures. While the CONSORT statement can be applied in 
RCTs in general, it focuses on randomized trials with two 
parallel arms. For other study types and intervention types 
(herbal medicinal products, acupuncture, non- pharmacologic) 
several CONSORT extensions have been developed. There are 
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also CONSORT extensions for harms and abstracts. All these 
products are accessible through the website www.consort-
statement.org. 
Since its appearance, CONSORT statement gains increasing 
support from more than 400 medical journals. Even significant 
editorial groups like international Committee of Medical 
Journal Editors and the Council of Science Editors endorse it, 
leading to reporting quality improvement. 
There is a number of published reviews assessing the reporting 
quality of RCTs in several medicinal subspecialty. Generally, 
they conclude that there is some improvement through the 
years but not at an expected level. In the field of Chemotherapy 
Induced Peripheral Neuropathy, progress is made in 
understanding the pathogenesis mechanisms and leads to the 
use of new drugs. As a result more and more RCTs are designed 
and conducted to evaluate these drugs. However the reporting 
quality of RCTsfor pain alleviating drugs in chemotherapy 
induced pain, so far, is not known. This knowledge would 
contribute to trial replication and to the credibility of results of 
RCTs. Health care providers and policy makers could draw safer 
conclusions evaluating the efficacies of the different agents and 
designing therapeutic strategies. 
In this context, aim of this study is to assess the reporting 
quality of RCTs for pharmaceutical treatment of Chemotherapy 
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3.1 Search strategy 
PubMed and Cochrane central databases were searched in 
August 2016 for reports on RCTs involving pharmaceutical 
treatment in Chemotherapy Induced Peripheral Neuropathy. 
On PubMed the following search terms were used: “CIPN AND 
treatment”, “CIPN AND antidepressants”, “CIPN AND 
anticonvulsants”, “CIPN AND Opioids”. The filters “article type” 
, “Humans” and “publication date” were customized as 
“Randomized Controlled Trials” and “from 01/01/2005 to 
31/12/2015” respectively. The same search terms were used on 
Cochrane CENTRAL database setting the following search limits: 
database as “Trials” and publication date as “between 2005 
and2015”. 
The initial search conducted for “CIPN AND treatment” 
demonstrated the antidepressants, the anticonvulsants and the 
opioids as the three main categories of drugs used in the 
treatment of CIPN. Thus, taking into consideration the 
literature as well, it was decided to broaden the search using 
these 3 terms. 
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What is more, because of the fact that year 2016 has not yet 
come to an end, data from 2005 to 2015 were used for the 
conduction of the search. 
 
3.2 Eligibility criteria- study selection 
Type of studies: eligible were only RCTs. To consider a study as 
RCT, participating subjects should have been randomized in at 
least two arms. Other types of studies such as retrospective, 
animal, genetic association studies were excluded. 
Type of participants: no limitations regarding to age, gender, 
origin. 
Type of intervention: eligible were studies testing 
antidepressants, anticonvulsants and opioids as drugs used in 
the treatment of CIPN. Acupuncture,Physiotherapy and other 
types of intervention were set as an exclusion criterion. 
Type of disease: RCTs were eligible, if they clearly stated that 
the intervention was tested for CIPN (Chemotherapy Induced 
Peripheral Neuropathy). Other types of neuropathy, such as 
diabetic neuropathy, were also exclusion criteria 
Type of publication: eligible were only full articles, written in 
English language, published in biomedical journals from 
01/01/2005 to 31/12/2015. Abstracts, editorials, reviews, 
meta-analyses, letters and other type of publication were to be 
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excluded from the analysis. 
From the records identified, duplications and abstracts were 
removed. Then an initial screening was performed on the basis 
of title and the remaining articles were read in abstract and full 
text to apply the eligibility criteria and select the reports 
included in the analysis. References of the articles included in 
the analysis were screened in order not to lose any relative 
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3.3 Data extraction and assessment of reporting quality 
according to CONSORT statement 
The selected articles were assessed for reporting quality using 
the revised CONSORT 2010 checklist (www.consort-
statement.org). This checklist is a questionnaire with25 items 
and totally 37 (sub-)items, evaluating if several aspects of the 
trial are reported and not whether they are implemented. 
Following the relevant guidelines, each (sub-)item for each 
eligible article was scored separately with 1 or 0. 1 was scored 
when the item was clearly reported in the article. Negative or 
alternative responses apart from yes and no were scored as 0. 
Thus, a total CONSORT score for each article was obtained with 
maximum probable total CONSORT score being equal to 37. 
3.4 Data analysis 
Total CONSORT scores of articles were analyzed initially using 
descriptive statistics methods. Taking into consideration that 
the revised CONSORT2010 checklist was first introduced in 
2010, three period groups were formed: one including articles 
from 2005 to 2010, another including articles published from 
2010 to 2015 and a combined group, taking all articles 
together. Medians and means were calculated. Pre- and post- 
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CONSORT groups were compared in total CONSORT scores to 
test for significant differences using Mann- Whitney U test for 2 
independent samples. 
Frequencies for each reporting item of the checklist were 
calculated for pre-, post- CONSORT and combined period group 
of articles. Additionally, it was intended to examine whether 
the reporting quality of trials improved after the introduction of 
the 2010 revised version of CONSORT. To achieve that, a Fisher 
exact test between the two period groups (pre- and post- 
CONSORT) was to be performed. Due to the small size of pre- 
and post- CONSORT 2010 groups, the Pearson’s chi-square test 
was rejected and results were interpreted cautiously. 
Categorical data were processed, frequencies were calculated 
and statistical tests were performed using IBM SPSS v21 
statistics package, provided by University of Thessaly. A P-value 
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4.1 Search results 
6829 records were identified searching PubMed. 6517 abstracts were 
removed as a consequence of search limits mentioned above. After 
that, screening on the remaining 312 records was performed and 259 
were rejected on the basis of title. The 53 reports left were assessed for 
eligibility, regarding abstracts and full text articles. Finally, 9 articles 











Records identified n=6829 
Records screened n=312 
Articles assessed for eligibility 
n=53 
Abstracts rejected n=6517 
Rejected on basis of title n=259 
Irrelevant n=139 
Trial design report n=1 
Other agent disease n=119 
 
Articles excluded n-44 
Unavailable full text n=2 
Animals/other studies n=32 
Non randomized trials n=10 
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Figure 1. Flow diagram of the study selection process 
 
4.2 Study Characteristics 
2 RCTs were published in Cancer Research Journal, 2 in Journal 
of Pain and Symptom Management, 2 in Supportive Care in 
Cancer, 1 in International Journal of Clinical Practice, 1 in 
Journal of The American Medical Association and 1 in Annals of 
Oncology. There were 6 publications in the pre-CONSORT 2010 
period (2005-2010), and 3 publications after 2010. Three major 
categories of pharmaceutical agents as well as combinations of 
the drugs of these categories, as tested intervention, were met:  
Anti-convulsants (Pregabalin, Lamotrigine and Gabapentin) in 3 
reports, anti-depressants 
(Venlafaxine,Amitriptyline,Duloxetine) in 3 reports 
andCannabinoidand ketamine in 1 reporteach, amitriptyline 
with ketamine in 1 report and finally baclofen, amitriptyline and 





Articles included in the analysis 
n=9 
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  Number of 
RCTs 
Journal  International Journal of clinicalPractice 
 Journal of American medical association 
 Journal of pain and symptom management 
 Cancer research 
 Supportive care in cancer 
































Control  Placebo 
 Other pharmaceutical substance 
7 
2 




Age of participants  Adults 
 Children  
9 
0 




Blinding  Blinded 
 Open- label 
8 
1 
CONSORT 2010 flow  Disposable 9 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 12:27:24 EET - 137.108.70.7
17 
 
diagram  Not disposable 0 
RCT: Randomized Controlled Trial 
CONSORT: Consolidated Standards of Reporting Trials 
Table 1. Characteristics of RCTs included in the analysis 
 
 
4.3 Reporting Quality 
The total CONSORT score of RCT reports, including the period 
2005-2015, ranged from 20 to 28 with a mean of 22 and a 
median equal to 21 (mean=22, SE=1,215  , SD=3,647 , median= 
21). Regarding the pre- and post-CONSORT period, mean total 
CONSORT scores were 23and 20 respectively. No statistically 
significant difference in total CONSORT score between pre- and 
post-CONSORT 2010 period groups was found (P=0,243>0.05, 
Mann Whitney U test). In table 2, the scoring process of the 
articles according to CONSORT 2010 checklist and the total 
scoresare presented. 
In table 3, items of the CONSORT 2010 checklist are reported in 
different frequencies among the articles included in the 
analysis. Abstract(Item 1b), Background(Item 2a), Eligibility 
criteria(Item 4a), Outcomes(Item 6a), Participant flow(Item 
13a) and Baseline(Item 15) are reported in all of the 9 RCTs. 
None of the RCTs report interim analysis(Item 7b) which refers 
to explanation of any interim analysis and stopping guidelines. 
Binary outcomes(Item 17b) which indicatespresentation of 
both absolute and relative effect sizes is not also reported in 
any of the 9 articles. 
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7 items have a frequency of 89% in the period 2005-2015. 
These are: Title(Item1a), Objectives(Item2b), Statistical 
methods(Item12a), Losses and exclusions (Item13b), Outcomes 
and estimations(Item17a), Harms(Item19) and 
Interpretation(Item22). Funding(Item25), 
Generalisability(Item22) and Numbers Analyzed (Item16) are 
reported in 78% of RCTs. The following most reported items are 
Protocol(Item24), Registration(Item 23), Additional 
analysis(Item12b), Type of randomization(Item8b), 
Intervention(Item5) and Trial design(Item3a) with a 67% 
proportion. Allocation sequence(Item8a) and 
Recruitment(Item14a) are reported in about half of RCTs, with 
a proportion of 56%. Less than half of articles report Allocation 
concealment(Item9) and Settings(Item4b) with a proportion of 
45%. 33% report Limitations(Item20) and Blinding(Item11a). 4 
items are reported in 22% of articles, including Trial 
end(Item14b), Sample size(Item7a), Changes to 
outcomes(Item6b) and changes to methods(Item3b). Ancillary 
analysis(Item18) and Similarity of interventions(Item11b) have 
a reporting frequency equal to 11%. Frequency of the 37 
reporting items for the pre- and post-CONSORT 2010 period are 
shown in Table 3. 
Between pre- and post-CONSORT 2010 period groups, we 
cannot see important progress in reporting Additional 
analysis(Item12b, p=0,003<0.05) and Generalisability(Item21, 
p=0,023<0.05). 
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Table 2. Scores of selected RCT reports using CONSORT 2010 checklist
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 12:27:24 EET - 137.108.70.7
21 
 
Table 3. Proportion of reporting of 37 data items in a total of 9 RCTs on treatment 
of CIPN by publication period from 2005-2015 (post-, per-CONSORT 2010 and 
combined) 
 
P-values obtained from Fisher exact tests. 
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Nowadays, more and more pharmaco-therapeutic drugs arise 
in the field of CIPN treatment. The current study aimed to 
assess the quality of RCTs on pharmaceutical treatment of 
chemotherapy induced peripheral neuropathy using the revised 
CONSORT 2010 statement and examine the CONSORT 2010 
effect on improving the reporting quality over time. 
However, the overall reporting quality of the selected RCTs 
stands on an average level without significant differences 
between pre- and post-CONSORT 2010 publication periods. 
Furthermore, reporting items are documented in a wide range 
of frequenciesacross the sum of the articles. Among the most 
frequently recorded items the following ones are included: 
Baseline data(Item15:the table showing baseline demographic 
and clinical characteristics for each group), 
Background(Item2a:Scientific background and explanation of 
rationale), Abstract(Item1b:Structured summary of trial design, 
methods, results, and conclusions),  Participant 
flow(Item12a:For each group, the numbers of participants who 
were randomly assigned, received intended treatment, and 
were analyzed for the primary outcome), and Eligibility 
criteria(Item4a:Eligibility criteria for participants). Conversely, 
identification as an RCT in the title, blinding, trial end, 
limitations, sample size and type of randomization seems really 
problematic. CONSORT 2010 adversely effects significantly on 
reporting Additional analysis and Generalisability.  
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Some of the items can be considered as key methodological 
items, because they can help reader to assess the validity of 
RCT. Blinding, allocation concealment and randomization 
implementation are significant to avoid bias. 
In this study, assessing the reporting quality of RCTs on 
pharmaceutical treatment of Chemotherapy Induced Peripheral 
Neuropathy during the last 10 years, conclusions about 
CONSORT 2010 effect on improving the reporting quality are 
not considered as credible. We have to mention that this might 
have become as a result of the small size of pre- and post-
CONSORT 2010 publication period groups (3 on the post- and 6 
on the pre-CONSORT 2010 group) and especially the small size 
of the pre-CONSORT 2010 group. 
Furthermore, this study has more limitations. Firstly, the 
assessment of RCT reports was conducted by only one person, 
the author. Probably the review by a second person would 
diminish the subjective factor. Secondly, the search was 
restrained in only 2 databases: PubMed and Cochrane Library 
and took under investigation only those published in English 
language and only for Humans. In contrast to those limitations, 
strength of this study is that all items of the last revised 2010 
CONSORT checklist were used in the process. 
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Finally, RCTs on pharmacological treatment of Chemotherapy 
Induced Peripheral Neuropathy published from 2005-2015 have 
insignificant reporting quality assessed using the CONSORT 
statement. Despite the fact that several items are well 
reported, poor reporting of some critical items makes the 
reports susceptible to bias, reduces their assessment to 
generate medical evidence and consequently limits health care 
decision. As new methods of treatment of CIPN are evolving, 
substantial obedience of their RCT reports to CONSORT 
statement is obliged in order to assess effectively their validity. 
Broader recommendations of CONSORT statement by medical 
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CONSORT 2010 checklist of information to include when 
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Section/Topic 
Item 
No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title  




2a Scientific background and explanation of rationale  
2b Specificobjectivesorhypotheses  
Methods 
Trialdesign 3a Description of trial design (such as parallel, factorial) including allocation ratio  
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons  
Participants 4a Eligibility criteria for participants  
4b Settings and locations where the data were collected  
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
 
6b Any changes to trial outcomes after the trial commenced, with reasons  
Samplesize 7a How sample size was determined  
7b When applicable, explanation of any interim analyses and stopping guidelines  
Randomisation:    
 8a Method used to generate the random allocation sequence  
Institutional Repository - Library & Information Centre - University of Thessaly










9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 
assessing outcomes) and how 
 
11b If relevant, description of the similarity of interventions  
Statisticalmethods 12a Statistical methods used to compare groups for primary and secondary outcomes  
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses  
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
 
13b For each group, losses and exclusions after randomisation,together with reasons  
Recruitment 14a Dates defining the periods of recruitment and follow-up  
14b Why the trial ended or was stopped  
Baselinedata 15 A table showing baseline demographic and clinical characteristics for each group  
Numbersanalysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 




17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
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*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the 
items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological 
treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date r eferences relevant to this checklist, see 
www.consort-statement.org. 
 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended  
Ancillaryanalyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)  
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses  
Generalisability 21 Generalisability (external validity, applicability) of the trial findings  
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence  
Other information 
 
Registration 23 Registration number and name of trial registry  
Protocol 24 Where the full trial protocol can be accessed, if available  
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders  
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